TL;DR:
- London-based startup Sable Bio raises €1.7 million in pre-seed funding led by Episode1 Ventures and supported by Seedcamp.
- Sable Bio aims to transform drug target safety evaluation for biotech and pharma companies.
- They seek partnerships with industry players and academic collaborations.
- The funding will be used to build a strong team, enhance technological infrastructure, and expand data capabilities.
- Sable Bio enables access to specialized biomedical data for informed decision-making in drug development.
- Unforeseen toxicity is a major challenge in drug discovery, and Sable Bio’s approach promises cost and time savings.
- The company was founded in 2023 and operates from London.
- Investors believe that Sable Bio’s use of LLMs will unlock previously inaccessible data, reducing time-to-market and costs in clinical trials.
Main AI News:
London-based Sable Bio, a forward-thinking B2B software startup, is poised to reshape the landscape of drug target safety evaluation for biotech and pharma companies. Their recent accomplishment of closing an oversubscribed €1.7 million pre-seed funding round, led by Episode1 Ventures and supported by Seedcamp, marks a significant milestone in their mission.
The company’s vision extends to establishing strategic partnerships with biotech, pharma, and healthtech firms, alongside fostering academic collaborations. This substantial funding injection will fuel the assembly of a top-tier team of scientists and engineers. Their collective expertise will drive the refinement and enhancement of Sable Bio’s core technological infrastructure, serving as the bedrock for an expansive data capability.
Josh Almond-Thynne, Co-founder of Sable Bio, expressed his enthusiasm, stating, “We are truly excited about this investment, which will empower Sable Bio to redefine the landscape of drug safety assessment and revolutionize the generation of actionable biomedical insights. Partnering with esteemed investors like Episode1 and Seedcamp positions us to construct an outstanding team and a platform that will accelerate the development of safer drugs for patients in need.“
Sable Bio’s innovative approach facilitates widespread access to specialized biomedical data, providing scientists from various domains with the tools to make informed decisions regarding the safety of specific drug targets. Given that unforeseen toxicity remains a significant obstacle in drug discovery endeavors, Sable Bio’s methodology offers substantial cost and time savings in the drug development process, ultimately expediting the delivery of safer medications to patients in dire need.
Founded in 2023 and headquartered in London, Sable Bio empowers scientists to identify and mitigate potential safety risks associated with drugs in development or on the verge of clinical trials by employing a suite of cutting-edge techniques.
Adam Shuaib, Partner at Episode 1, weighed in on the significance of Sable Bio’s mission, remarking, “Ensuring target safety remains a pivotal challenge in the drug discovery realm, and co-founders Alex and Josh, both eminent scientists, are uniquely positioned to tackle this intricate issue. The emergence of LLMs (Large Language Models) marks a revolutionary technological leap, enabling Sable Bio to unlock previously inaccessible troves of data within the scientific literature, ultimately reducing time-to-market and the costs associated with clinical trials.”
Tom Wilson, Partner at SeedCamp, added his perspective, saying, “The journey from drug discovery to market release is often protracted, with toxicity being a major stumbling block that leads to delays or even project failures. Sable Bio is perfectly positioned to address this issue by providing timely access to critical data for those who need it most. Leveraging LLMs to unearth data that was previously out of reach, co-founders Alex and Josh combine scientific excellence with domain-specific expertise and entrepreneurial drive, making them the ideal leaders to spearhead Sable Bio’s transformative mission. We are delighted to partner with them on this journey.“
Conclusion:
Sable Bio’s successful funding round signifies growing interest and potential in the field of drug safety assessment. Their innovative approach, backed by investors, has the potential to significantly accelerate drug development, reduce costs, and address critical challenges in the biotech and pharma sectors. This development signals a positive outlook for the market as it moves towards more data-driven and efficient drug discovery processes.
